explore -WSS

explore

author：hotspot 2025-10-01 23:07:04 - browse：86851

Cambridge: Biogen — Ruby Wallau for STAT

A plan to use new genetic techniques to treat non-genetic forms of ALS failed in an early study, Ionis and Biogen announced Thursday. The companies said they would discontinue the program.

In the randomized, 99-person trial, the companies tested a drug designed to silence a gene called ATXN2. Over the last decade, numerous drugs have been built to silence genes in ALS patients, but most of them have, fittingly, focused on rare genetic forms of ALS, where neurons die largely because of the work of a single mutated stretch of DNA.

This approach has led to an approved drug for one very small subset of ALS cases, driven by the gene SOD1, and drugs for other genes are in trials. But only perhaps 10% — or at most 20% — of ALS cases are genetic. The hope, based on some genetic data and promising mice experiments, was that lowering ATXN2 would help any patient who develops ALS.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Jerome Adams on the need for new antivirals for Covid
Next article： Search warrant issued in 1996 disappearance of Kristin Smart

WSS

What to watch for from Zogenix and Amicus clinical trials

Man pleads guilty to raping Ohio girl who ended up traveling across state lines for abortion

Suspect in Ukraine detonates explosives at a courthouse, killing himself and wounding 2 officers

Philadelphia mass shooting: Few answers in apparently random attack as suspect charged with murder

Truvian presents data for its desktop blood

Will the FTC rein in IQVIA's health data empire?

knowledge

explore

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

focus

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Pentagon will tighten controls on classified information after Discord leak

Cancer drug shortages should be causing more outrage

Adele warns fans about throwing things at performers onstage

ChatGPT in medicine: STAT answers readers' burning questions

Man with guns arrested near Obama home 'attempted to evade' Secret Service: Prosecutors

How one medical school became remarkably diverse

Russian fighter jet damages US Reaper drone with flare over Syria: Officials

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

China dismisses criticism of top diplomat's comments appearing to push for race

focus

Accuser says Kevin Spacey grope wasn't a caress: ‘It was like a cobra ... angry’

Dems pitch expanding Medicare power to negotiate drug prices

Adele warns fans about throwing things at performers onstage

Gov. Ron DeSantis' push for 'civics' education: What does it look like?

Former New York Mayor de Blasio and wife announce separation, but not divorce

What to watch for from Zogenix and Amicus clinical trials

explore

hotspot

Wikipedia

focus